The UK’s blue-chip index, FTSE 100, experienced a decline on Tuesday, primarily influenced by the performance of GSK. This movement followed the healthcare company’s announcement regarding its intention to acquire shares of U.S.-based drug developer Nuvalent for $10.6 billion, a strategic move aimed at enhancing its lung cancer treatment portfolio. The blue-chip FTSE 100 index Read More